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Conclusions: AT is frequent after TAVR and associated with major bleeding events and
increased mortality. Larger studies are needed to confirm those results.
TCT-899
Risk of Respiratory Failure After Minimally Invasive Transapical Aortic
Valve Implantation
Martin Haensig1, David Holzhey1, Michael Borger1, Sven Lehmann1, Axel Linke1,
Joerg Seeburger1, Gerhard Schuler1, Friedrich Mohr1
1University of Leipzig - Heart Center, Leipzig, Germany
Background: Impaired respiratory function is believed to be a risk factor for transapical
aortic valve implantation (TA-AVI). The purpose of this study was to investigate the
incidence, predictors and impact of acute and chronic respiratory failure (ARF and CRF)
on procedural success and outcome.
Methods: 350 consecutive ‘high-risk’ patients, age 81.8 6.4 years, 66.3% female, were
included during a 4-year period. Preoperative estimated FEV1 was 91.9  33.6%. Mean
logistic EuroSCORE was 31.0 15.9% and mean STS-Score 12.0 7.7%. An uni- and
multivariate logistic regression analysis was performed.
Results: Regarding the postoperative respiratory outcome, ARF occurred in 14.9% and
interstitial lung disease (OR 23.40, p 0.01), transfusion 4 RBC units (OR 15.35,
p 0.001), brief reactive psychosis (OR 8.39, p 0.001), age  80 yrs (OR 3.66,
p  0.035) and vital capacity  60% (OR  3.23, p  0.025) were independent risk
factors for this event. Postoperative re-intubation was required in 17.1%. Vital capacity
60% (OR  2.94, p  0.046) and transfusion  4 RBC units (OR  16.00, p  0.001)
were independent risk factors for CRF. Short-term and long-term survival was explicitly
lower in the ARF, CRF and re-intubation groups (p  0.001 each).
Conclusions: Interstitial lung disease, age  80 yrs and vital capacity  60% are
preoperative risk factors for impaired respiratory outcome. Further studies will define if
the same risk factors can be expected using a transfemoral approach.
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Background: To evaluate the incidence and predictors of high degree atrioventricular
block (HDAVB) and permanent pacemaker implantation (PPM) following surgical aortic
valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI).
Methods: We analyzed clinical, electrocardiographic, echocardiographic and peri-
procedural data from 336 patients (pts) without prior pacemaker who underwent TAVI
with either CoreValve (n130) or Edwards-Sapien (n206) prostheses between 2007
and 2011 and from 210 elderly pts (75 years) undergoing SAVR between 2005 and
2010 in our centre.
Results: Mean age was similar in TAVI:79.47.3 vs. SAVR:79.072.86 years
(p0.45). TAVI exhibited an higher risk profile (Log Euroscore 22.915.8% in TAVI vs.
13.111.8% in SAVR, p0.0001). HDAVB occurred in 10% SAVR vs. 13.9% TAVI
pts (p0.2) with an higher resolution in SAVR (90.5%) and 2 pts (0.95%) implanted
PPM. PPM implantation was higher in TAVI (n51, 15.2%, p0.001) mostly due to
HDAVB (86.3%) and was lower in Edwards (6.7%) vs. CoreValve (23.1%) group
(p0.001). The main causes of PPM implantation were: 3rd AVB (40pts, 78.5%), 2nd
AVB Mobitz 2 (2pts, 4%), symptomatic LBBB and 1st AVB (2pts, 4%), atrial fibrillation
with a ventricular rate40/min (3pts, 6%), QRS widening (1pt, 1.9%), LBBB with sinus
bradycardia (2pts, 4%) and brady-tachy syndrome (1pt, 1.9%). The median time from
TAVI to PPM was 2 days (IQR0-12) and from SAVR was 13.5 days (IQR12-15). On
multivariable analysis, the predictors of HDAVB were pre-existing RBBB (OR:5.1 95%
CI 1.9-16.5; p0.005) and LAH (OR:3.9 95% CI 1.3-11.1, p0.011) in SAVR, whereas
ejection fraction below 35% (p0.052), CoreValve prosthesis (p0.001), post-dilatation
(p0.001) and RBBB at baseline (p0.001) predicted HDAVB in TAVI. On only
univariate analysis, the depth of valve implantation (p0.001) and ratio between valve
and annulus size (p0.001) predicted HDAVB after TAVI.
Conclusions: The need for PPM following TAVI was higher than SAVR (13.1 vs.
0.95%). Pre-existing RBBB and LAH were risk factors for HDAVB after SAVR. The
predictive factors for complete AVB and PPM in TAVI patients were pre-existing RBBB,
lower ejection fraction, CoreValve prosthesis and valve postdilatation.
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Background: Concomitant mitral regurgitation (MR) is frequently present prior to
transapical aortic valve implantation (TA-AVI). The aim was to study the impact of MR
on outcome and the effect of TA-AVI on MR using the Edwards SAPIENTM prosthesis.
Methods: A total of 439 patients, age 81.5  6.4 years, 64.0% female, unterwent
TA-AVI between Feb/2006 and Aug/2011. Mean logistic EuroSCORE was 29.7 
15.7% and mean STS-Score 11.4%  7.6%. Outcome was assessed in patients with
absent (9.8%),  mild (58.5%), moderate (29.7%) and severe (2.0%) MR by pre- and
postoperative echocardiography.
Results: Patients with moderate/severe MR versus  mild MR had an increased
in-hospital mortality (HR 2.69, 95% CI 1.43-5.06, p0.002), but a comparable 4-year
survival (HR  0.73, 95% CI 0.27-1.93, p  0.520). During postoperative echocardio-
graphic examination, there was an overall improvement in mitral incompetence (absent in
23.7%, mild in 58.6%, moderate in 17.7%, and severe in none). Independent multivariate
predictor’s of improved MR were a maximum trans-aortic gradient  50 mmHg (OR 
14.35, p  0.02), preoperative vena contracta width of the mitral valve  5.0 mm (OR 
8.93, p 0.004), left-ventricular posterior wall dimension  1.6 cm (OR  7.19, p 
0.001) and LVEF  60% (OR  4.92, p  0.007).
Conclusions: Moderate/severe MR prior to TA-AVI is associated with an increased
early, but a comparable late mortality. We observed an overall improved mitral valve
performance possibly by reducing closure forces acting on the mitral valve.
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Background: Registry data and recent a randomized trail have established the safety and
efficacy of TAVR in high risk operable and non-operable patients. Due to differences
between the two common valve types procedural results and outcome may differ. The
web-based on-line Swedish TAVI register have since the beginning 2008 captured all
implant procedures, 1 month and 1 year FU as well as it tracks mortality in 100% of
patients.
Methods: TAVI-procedures were only performed in the seven university hospital with
cardiac surgical backup. Three hospitals used the CoreValve and four the Edwards Sapien
device, none used both. Mortality tracking was performed via the national population
registry.
Results: From 2008-2010; 568 TAVI procedures were performed. The use of the two
devices was similar until 2011 with an increase in CoreValve procedures 122 vs. 87
Sapien. Approximately an equal number of men and women have been treated with a
mean age of 82. An increase in transfemoral procedures compared to other access routes
is observed. In 2011 the logistic Euroscore was higher for the CoreValve (27.5) compared
to the Sapien (25.0). Procedural results are presented in table 1.
Conclusions: From 2008 till 2011 the number of TAVI procedures shows a moderate
increase. Logistic Euroscore remains unchanged. Stroke numbers are low and have
decreased from 3 to 1.5 %. The 30 days and 1 year all-cause mortality rate is 6.4% and
14%. Besides the higher number of pacemaker implants in the CoreValve group no major
differences were seen between the two devices. The final analysis of the data will be
presented at the meeting.
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Table 1: Results from the Swedish TAVI registry 2008-2011
CoreValve Sapien
TAVI Sweden
2008-2011 n313 n252
Access site Transfemoral Transsubclavian Transfemoral Transapical
n 291 n22 n93 n159
Euroscore log 23.5 25.0
Device
Success %
97.8 95.8
All cause
mortality 30-
days %
5.5 7.5
All cause
mortality 1-
year %
13.3 17.0
Myocardial
infarction %
1.0 1.3
Acute Kidney
injury (2011
only) %
6.0 2.5
Life-
threatening
bleeding %
5.1 12.1
Major
vascular
bleeding %
10.2 6.4
Major stroke
%
2.1 1.9
New
permanent
pacemaker %
16.4 5.7
Fluoroscopy
time mean
minutes
29,2 22,0
Contrast
media mean
ml
177,5 134,0
Length of
Hospital stay
days
7,3 9,8
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Background: To compare the incidence and clinical significance of new bundle branch
block in patients undergoing transcatheter aortic valve implantation (TAVI) with the
Medtronic CoreValve and Edwards-Sapien prosthesis.
Methods: We analyzed data from 336 patients (pts) with no prior pacemaker who
underwent TAVI with CoreValve (n130) or Edwards (n206) prosthesis between 2007
and 2011 in our centre. We examined the 12-lead ECGs and documented the conduction
disturbances after TAVI and before discharge as compared to baseline.
Results: Mean age was similar in CoreValve (79.47.3 years) vs. Edwards group
(79.78.1 years, p0.43). New onset of left bundle branch block (LBBB) was
documented in 65 (19.3%) pts: 21 (32.2%) in Edwards vs. 44 (67.7%) in CoreValve pts
(p0.001). Of them 18 (27.7%) pts showed also a 1st atrioventricular block (AVB): 3 in
Edwards and 16 in CoreValve pts (p0.001). Permanent Pacemaker implantation (PPM)
was required in 9 (13.8%) pts because of 3rd AVB (Edwards n3; CoreValve n4),
LBBB and 1st AVB (CoreValve n1) and LBBB with sinus bradycardia (CoreValve
n1). In 14 (21.5%) pts, LBBB was temporary (5 pts, 23.8% Edwards vs. 9pts, 20.4%
CoreValve), whereas LBBB persisted in 61.9% of Edwards and in 65.9% of CoreValve
pts (p0.5) at discharge. On multivariable analysis, the predictors of LBBB were:
CoreValve prosthesis (OR:5.3 95%-CI:2.9-9.8, p0.001), and previous CABG (OR:1.9,
95%-CI:0.9-4, p0.064). New onset of LBBB was not a predictor of overall (log rank
p0.56) and cardiovascular mortality (log rank p0.61). A new onset of right bundle
branch block (RBBB) was documented in 12 (3.6%) pts (6 both in Edwards and in
CoreValve pts): 1.5% with left anterior hemiblock (LAH), 0.3% with 1st AVB and 0,6%
with both LAH and 1st AVB. There were no statistically significant differences between
Edwards and CoreValve prosthesis. 9 pts developed a new isolated 1st AVB.
Conclusions: New LBBB and RBBB are frequent intraventricular conduction distur-
bances after TAVI with a higher incidence in CoreValve prosthesis. In the majority of pts,
the LBBB persists but is not a predictor of overall and cardiovascular mortality. These
preliminary conclusions needs to be confirmed in a lorger cohort of patients.
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Background: The mechanisms of paraprosthetic aortic regurgitation (PPAR) in trans-
catheter valve intervention is related to patient and procedural factors. We studied the
association of balloon valvuloplasty and implant depth with PPAR.
Methods: We conducted a multicenter analysis of 295 patients undergoing Medtronic
CoreValve implantation with prior CT annular sizing. Significant PPAR was defined as
moderate or severe angiographic regurgitation. Implant depth was measured as the mean
distance from the nadir of the non- and left coronary sinuses to the distal valve frame
angiographically. Pre-implantation nominal and achieved balloon size during valvulo-
plasty were recorded.
Results: The majority of patients had mild (35.5%), trivial (20.7%) or no (7.6%) PPAR
with significant PPAR observed in 36% of patients. Significant PPAR was associated with
a larger mean native annular diameter (p0.01) and annulus to valve size ratio (p0.03),
Fig 1. Significant PPAR was also associated with increased depth of implantation
(p0.035). Although nominal balloon and native valve sizes were well matched,
underexpanded balloon size was associated with significant PPAR (p0.04). 13.7% of
patients had post dilatation of the implant.
Conclusions: Significant paraprosthetic aortic regurgitation following Medtronic Cor-
eValve implantation is associated with larger native valve dimensions and increased depth
of implant. Adequacy of balloon valvuloplasty may also predict PPAR.
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